Given that obesity is a strong risk factor for breast cancer and potentially also a risk factor for AH in postmenopausal women, it is plausible that IGFBP-2 could confer protection against breast cancer development via inhibition of the adipogenesis that leads to obesity. Here, IGFBP2 is linked to obesity due to melanocortin 4 receptor deficiency.